Bio-Rad Laboratories, Inc. (BIO.B)
NYSE: BIO.B · Real-Time Price · USD
315.00
0.00 (0.00%)
Jun 3, 2026, 4:00 PM EDT - Market closed
Bio-Rad Laboratories Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,590 | 2,583 | 2,567 | 2,671 | 2,802 | 2,923 | |
Revenue Growth (YoY) | 1.92% | 0.65% | -3.92% | -4.67% | -4.12% | 14.81% |
Cost of Revenue | 1,247 | 1,243 | 1,188 | 1,244 | 1,235 | 1,284 |
Gross Profit | 1,343 | 1,340 | 1,379 | 1,427 | 1,567 | 1,638 |
Selling, General & Admin | 847.9 | 844.3 | 814 | 841.7 | 827.8 | 877.12 |
Research & Development | 265 | 275.6 | 295.9 | 247.4 | 256.9 | 260.64 |
Other Operating Expenses | 172.8 | 172.8 | - | - | - | - |
Total Operating Expenses | 1,286 | 1,293 | 1,110 | 1,089 | 1,085 | 1,138 |
Operating Income | 57.6 | 47.2 | 269 | 337.8 | 482.6 | 500.34 |
Interest Expense | -49.3 | -49 | -48.9 | -49.4 | -38.1 | -1.55 |
Other Non-Operating Income (Expense) | 214 | 997.3 | -2,563 | -1,139 | -5,149 | 4,950 |
Total Non-Operating Income (Expense) | 164.7 | 948.3 | -2,612 | -1,188 | -5,187 | 4,949 |
Pretax Income | 222.7 | 995.5 | -2,343 | -850.1 | -4,704 | 5,449 |
Provision for Income Taxes | 53.5 | 235.6 | -498.3 | -212.8 | -1,077 | 1,195 |
Net Income | 168.8 | 759.9 | -1,844 | -637.3 | -3,628 | 4,254 |
Net Income to Common | 168.8 | 759.9 | -1,844 | -637.3 | -3,628 | 4,254 |
Net Income Growth | - | - | - | - | - | 11.54% |
Shares Outstanding (Basic) | 27 | 27 | 28 | 29 | 30 | 30 |
Shares Outstanding (Diluted) | 27 | 27 | 28 | 29 | 30 | 30 |
Shares Change (YoY) | -3.75% | -3.31% | -3.41% | -1.93% | -1.40% | 0.16% |
EPS (Basic) | 6.11 | 27.87 | -65.36 | -21.82 | -121.79 | 142.61 |
EPS (Diluted) | 6.07 | 27.85 | -65.36 | -21.82 | -121.79 | 140.83 |
EPS Growth | - | - | - | - | - | 11.35% |
Shares Outstanding | 26.83 | 26.99 | 28.01 | 28.52 | 29.6 | 29.93 |
Free Cash Flow | 357.2 | 374.6 | 289.6 | 218.2 | 81.6 | 535.72 |
Free Cash Flow Growth | -4.64% | 29.35% | 32.72% | 167.40% | -84.77% | 12.45% |
Free Cash Flow Per Share | 13.21 | 13.73 | 10.26 | 7.47 | 2.74 | 17.73 |
Gross Margin | 51.87% | 51.87% | 53.73% | 53.42% | 55.93% | 56.05% |
Operating Margin | 2.22% | 1.83% | 10.48% | 12.65% | 17.22% | 17.12% |
Profit Margin | 6.52% | 29.42% | -71.86% | -23.86% | -129.45% | 145.57% |
FCF Margin | 13.79% | 14.50% | 11.28% | 8.17% | 2.91% | 18.33% |
EBITDA | 98.5 | 212.6 | 420.6 | 483.7 | 482.6 | 500.34 |
EBITDA Margin | 3.80% | 8.23% | 16.39% | 18.11% | 17.22% | 17.12% |
EBIT | 57.6 | 47.2 | 269 | 337.8 | 482.6 | 500.34 |
EBIT Margin | 2.22% | 1.83% | 10.48% | 12.65% | 17.22% | 17.12% |
Effective Tax Rate | 24.02% | 23.67% | 21.27% | 25.03% | 22.89% | 21.93% |